Citius Pharmaceuticals (CTXR) EBITDA Margin (2025 - 2026)

Citius Pharmaceuticals' (CTXR) quarterly EBITDA Margin came in at 785.39% in Q2 2026, up 59.33% quarter-over-quarter from 1930.96% in Q1 2026.

Analysis

Citius Pharmaceuticals (CTXR) EBITDA Margin (2025 - 2026) Analysis & Trends

Citius Pharmaceuticals (CTXR) has reported EBITDA Margin for 2 consecutive years, with 785.39% the latest figure, recorded in Q2 2026.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Johnson & Johnson	641.31 Bn	620.55 Bn	17.26 Bn	28.21%
2	AbbVie	445.49 Bn	438.92 Bn	12.70 Bn	37.86%
3	Merck	357.41 Bn	350.27 Bn	12.21 Bn	-3.52%
4	Novartis Ag	267.66 Bn	259.97 Bn	11.24 Bn	32.97%
5	Pfizer	156.81 Bn	145.11 Bn	10.94 Bn	28.37%
6	Sanofi	52.17 Bn	44.78 Bn	10.79 Bn	9.03%
7	Revolution Medicines	42.94 Bn	42.94 Bn	-	-
8	Incyte	24.61 Bn	20.07 Bn	1.57 Bn	41.69%
9	United Therapeutics	21.31 Bn	18.64 Bn	683.80 Mn	42.23%
10	Citius Pharmaceuticals	15.70 Mn	15.70 Mn	1.00 Mn	-785.39%

Historic Data

Download Data